Jason A. Dominitz

Jason A. Dominitz

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Jason A. Dominitz

National Gastroenterology and Hepatology Program, Veterans Health Administration, Washington, District of Columbia, USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
SISteven O. Ikenberry
Steven O. Ikenberry
TJTerry L. Jue
Terry L. Jue
MAMichelle A. Anderson
Michelle A. Anderson
VAVasundhara Appalaneni
Vasundhara Appalaneni
SBSubhas Banerjee
Subhas Banerjee
JDJason A. Dominitz
Jason A. Dominitz

1 July 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DRDouglas K. Rex
Douglas K. Rex
CBC. Richard Boland
C. Richard Boland
JDJason A. Dominitz
Jason A. Dominitz
FGFrancis M. Giardiello
Francis M. Giardiello
DJDavid A. Johnson
David A. Johnson
DRDouglas J. Robertson
Douglas J. Robertson

1 January 2020 in Gastroenterology
Verified
Journal Article
Closed access
ULUri Ladabaum
Uri Ladabaum
JDJason A. Dominitz
Jason A. Dominitz
CKCharles Kahi
Charles Kahi
RSRobert E. Schoen
Robert E. Schoen

1 July 2017 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
DRDouglas K Rex
Douglas K Rex
RBRichard C Boland
Richard C Boland
JDJason A Dominitz
Jason A Dominitz
FGFrancis M Giardiello
Francis M Giardiello
DJDavid A Johnson
David A Johnson
DRDouglas J Robertson
Douglas J Robertson
This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy. Colonoscopy and FIT are recommended as tests of choice when multiple options are presented as alternatives. A risk-stratified approach is also appropriate, with FIT screening in populations with an estimated low prevalence of advanced neoplasia and colonoscopy screening in high prevalence populations. The second-tier tests include CT colonography every 5 years, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years. These tests are appropriate screening tests, but each has disadvantages relative to the tier 1 tests. Because of limited evidence and current obstacles to use, capsule colonoscopy every 5 years is a third-tier test. We suggest that the Septin9 serum assay (Epigenomics, Seattle, Wash) not be used for screening. Screening should begin at age 50 years in average-risk persons, except in African Americans in whom limited evidence supports screening at 45 years. CRC incidence is rising in persons under age 50, and thorough diagnostic evaluation of young persons with suspected colorectal bleeding is recommended. Discontinuation of screening should be considered when persons up to date with screening, who have prior negative screening (particularly colonoscopy), reach age 75 or have <10 years of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. Persons with a family history of CRC or a documented advanced adenoma in a first-degree relative age <60 years or 2 first-degree relatives with these findings at any age are recommended to undergo screening by colonoscopy every 5 years, beginning 10 years before the age at diagnosis of the youngest affected relative or age 40, whichever is earlier. Persons with a single first-degree relative diagnosed at ≥60 years with CRC or an advanced adenoma can be offered average-risk screening options beginning at age 40 years.

1 June 2002 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
GEGlenn M Eisen
Glenn M Eisen
TBTodd H Baron
Todd H Baron
JDJason A Dominitz
Jason A Dominitz
DFDouglas O Faigel
Douglas O Faigel
JGJay L Goldstein
Jay L Goldstein
AEAmerican Society For Gastrointestinal Endoscopy
American Society For Gastrointestinal Endoscopy

1 January 2010 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JMJohn T. Maple
John T. Maple
TBTamir Ben-Menachem
Tamir Ben-Menachem
MAMichelle A. Anderson
Michelle A. Anderson
VAVasundhara Appalaneni
Vasundhara Appalaneni
SBSubhas Banerjee
Subhas Banerjee
JDJason A. Dominitz
Jason A. Dominitz